CO5630034A2 - Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas - Google Patents
Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadasInfo
- Publication number
- CO5630034A2 CO5630034A2 CO05114676A CO05114676A CO5630034A2 CO 5630034 A2 CO5630034 A2 CO 5630034A2 CO 05114676 A CO05114676 A CO 05114676A CO 05114676 A CO05114676 A CO 05114676A CO 5630034 A2 CO5630034 A2 CO 5630034A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- composition according
- aterosclerosis
- dyslipidemias
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
1.- Una composición farmacéutica compuesta por ácido nicotínico, o una sal o solvato del mismo farmacéuticamente aceptable, u otro agonista del receptor de ácido nicotínico y un antagonista del receptor DP en combinación con un vehículo farmacéuticamente aceptable.2.- Una composición farmacéutica según la reivindicación 2, que está compuesta por ácido nicotínico y un antagonista del receptor DP en combinación con un vehículo farmacéuticamente aceptable.3.- Una composición farmacéutica según la reivindicación 2, en la que el antagonista de DP se selecciona del grupo formado por: o una sal o solvato del mismo farmacéuticamente aceptable.4.- Una composición farmacéutica según la reivindicación 3, en la que el antagonista de DP se selecciona del grupo compuesto por los compuestos A, B, D, E, X, AA, AF, AG, AH, Al y AJ.5.- Una composición farmacéutica según las reivindicaciones 1, 2, 3, ó 4, que además comprende un compuesto inhibidor de la HMG Co-A reductasa.6.- Una composición farmacéutica según la reivindicación 5, en la que el compuesto inhibidor de la HMG Co-A reductasa es simvastatina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47066503P | 2003-05-15 | 2003-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5630034A2 true CO5630034A2 (es) | 2006-04-28 |
Family
ID=33476734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05114676A CO5630034A2 (es) | 2003-05-15 | 2005-11-10 | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
Country Status (45)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094830A2 (en) * | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
DE202005022112U1 (de) | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
US8165517B2 (en) * | 2005-01-19 | 2012-04-24 | The Trustees Of The University Of Pennsylvania | Methods for identifying inhibitors of vascular injury |
JP2008530250A (ja) * | 2005-02-17 | 2008-08-07 | メルク エンド カムパニー インコーポレーテッド | アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法 |
JP2008538277A (ja) * | 2005-02-18 | 2008-10-23 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 脂質関連障害の治療用の組成物および方法 |
US7750015B2 (en) * | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AU2006247695B2 (en) * | 2005-05-17 | 2012-08-09 | Merck Sharp & Dohme Corp. | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2007027532A2 (en) * | 2005-08-29 | 2007-03-08 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
CN101305010A (zh) * | 2005-09-01 | 2008-11-12 | 阿雷生物药品公司 | Raf抑制剂化合物及其用法 |
EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
WO2007075702A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
EP1965862A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
JP2009525961A (ja) * | 2006-01-20 | 2009-07-16 | シェーリング コーポレイション | 異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環 |
US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
MX2009002924A (es) | 2006-09-15 | 2009-05-28 | Schering Corp | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. |
CN101583612A (zh) * | 2006-09-15 | 2009-11-18 | 先灵公司 | 治疗脂质代谢障碍的氮杂环丁酮衍生物 |
EP2091534A1 (en) * | 2006-09-15 | 2009-08-26 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
US20100260841A1 (en) * | 2007-02-08 | 2010-10-14 | Paolini John F | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
US20090076117A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched laropiprant |
CN101559058B (zh) * | 2008-04-16 | 2011-07-20 | 北京本草天源药物研究院 | 一种治疗血脂异常的药物组合物 |
CN102083466A (zh) * | 2008-05-20 | 2011-06-01 | 科莱尼斯医疗公司 | 用于组合疗法的烟酸和nsaid |
US8507473B2 (en) | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
EP2341773A4 (en) * | 2008-09-24 | 2012-03-07 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
KR101699912B1 (ko) | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
BR112012023039A2 (pt) | 2010-03-16 | 2016-05-17 | Aventis Pharma Inc | pirimidina substituída como um antagonista de receptor prostaglandina d2 |
CN103038228A (zh) | 2010-03-16 | 2013-04-10 | 安万特药物公司 | 作为前列腺素d2受体拮抗剂的取代的嘧啶类化合物 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3535326A (en) * | 1967-03-06 | 1970-10-20 | Sumitomo Chemical Co | Certain tetrahydro carboline derivatives |
BE787444A (fr) * | 1971-08-13 | 1973-02-12 | Hoffmann La Roche | Composes polycycliques |
US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
JPS6352514B2 (es) | 1977-09-30 | 1988-10-19 | Rca Corp | |
US4342767A (en) | 1980-01-23 | 1982-08-03 | Merck & Co., Inc. | Hypocholesteremic fermentation products |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
US4808608A (en) * | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
US4940719A (en) * | 1986-03-27 | 1990-07-10 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole esters, pharmaceutical compositions and use |
US4775680A (en) * | 1987-07-21 | 1988-10-04 | Merck & Co., Inc. | Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5190972A (en) * | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
CA2218696A1 (en) * | 1995-04-19 | 1996-10-24 | L. Jackson Ii Roberts | Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs |
WO1997016455A1 (en) | 1995-10-31 | 1997-05-09 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents |
WO1997016424A1 (en) | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
ATE228354T1 (de) | 1995-12-22 | 2002-12-15 | Kowa Co | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium |
US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
BR9815548A (pt) * | 1997-07-31 | 2000-11-07 | Kos Pharma Inc | Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição |
HUP0101110A3 (en) * | 1997-10-27 | 2002-06-28 | Reddys Lab Ltd Dr | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
WO2000034240A1 (en) | 1998-12-07 | 2000-06-15 | Schering Corporation | Process for the synthesis of azetidinones |
EA200100704A1 (ru) | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
EP2281899A3 (en) | 1999-04-05 | 2012-01-04 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone |
US6593078B1 (en) | 1999-04-16 | 2003-07-15 | Schering Corporation | Use of azetidinone compounds |
IT1306141B1 (it) * | 1999-05-17 | 2001-05-30 | Giampiero Valletta | Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche. |
WO2003022814A1 (fr) | 2001-09-07 | 2003-03-20 | Ono Pharmaceutical Co., Ltd. | Derives d'indole |
CN1179945C (zh) | 2000-03-09 | 2004-12-15 | 小野药品工业株式会社 | 吲哚衍生物、其制备方法及用途 |
US20010047027A1 (en) * | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
JP2002008186A (ja) * | 2000-06-23 | 2002-01-11 | Mitsubishi Heavy Ind Ltd | 車種識別装置 |
US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
JP3889563B2 (ja) * | 2000-09-13 | 2007-03-07 | 三洋電機株式会社 | 映像信号処理回路 |
AU2002242910A1 (en) | 2001-04-11 | 2002-10-28 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
WO2002094830A2 (en) * | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
KR20040095302A (ko) * | 2002-03-19 | 2004-11-12 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 화합물 및 그 화합물을 유효 성분으로서함유하는 약제 |
RU2362555C2 (ru) * | 2002-06-03 | 2009-07-27 | Новартис Аг | Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний |
US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
JP4129960B2 (ja) * | 2005-07-01 | 2008-08-06 | タキゲン製造株式会社 | ステー |
-
2004
- 2004-05-05 AR ARP040101527A patent/AR041089A1/es unknown
- 2004-05-06 JO JO200454A patent/JO2564B1/en active
- 2004-05-06 PE PE2004000463A patent/PE20050552A1/es not_active Application Discontinuation
- 2004-05-10 MY MYPI20041729A patent/MY140639A/en unknown
- 2004-05-13 WO PCT/US2004/014980 patent/WO2004103370A1/en active Application Filing
- 2004-05-13 EP EP10182413A patent/EP2286816A1/en not_active Withdrawn
- 2004-05-13 PT PT04785539T patent/PT1624871E/pt unknown
- 2004-05-13 RS RS20120498A patent/RS20120498A1/en unknown
- 2004-05-13 NZ NZ572515A patent/NZ572515A/en not_active IP Right Cessation
- 2004-05-13 PL PL04785539T patent/PL1624871T3/pl unknown
- 2004-05-13 GT GT200400098A patent/GT200400098A/es unknown
- 2004-05-13 RS RS20120499A patent/RS20120499A1/en unknown
- 2004-05-13 ME MEP-601/08A patent/MEP60108A/xx unknown
- 2004-05-13 NZ NZ543399A patent/NZ543399A/en not_active IP Right Cessation
- 2004-05-13 PT PT09163448T patent/PT2116244E/pt unknown
- 2004-05-13 PL PL09163448T patent/PL2116244T3/pl unknown
- 2004-05-13 RS YU20050777A patent/RS52731B/sr unknown
- 2004-05-13 UA UAA200512018A patent/UA89615C2/ru unknown
- 2004-05-13 JP JP2006515355A patent/JP4637833B2/ja not_active Expired - Fee Related
- 2004-05-13 KR KR1020077029888A patent/KR100960749B1/ko not_active IP Right Cessation
- 2004-05-13 KR KR1020057021795A patent/KR100806008B1/ko active IP Right Grant
- 2004-05-13 CA CA2525772A patent/CA2525772C/en not_active Expired - Fee Related
- 2004-05-13 EP EP04785539A patent/EP1624871B1/en not_active Expired - Lifetime
- 2004-05-13 US US10/844,773 patent/US20040229844A1/en not_active Abandoned
- 2004-05-13 EA EA200501817A patent/EA009744B1/ru not_active IP Right Cessation
- 2004-05-13 CN CN2012100149106A patent/CN102526735A/zh active Pending
- 2004-05-13 CN CNB2004800128531A patent/CN100441184C/zh not_active Expired - Fee Related
- 2004-05-13 DE DE602004022036T patent/DE602004022036D1/de not_active Expired - Lifetime
- 2004-05-13 EP EP09163448A patent/EP2116244B1/en not_active Expired - Lifetime
- 2004-05-13 DK DK09163448.5T patent/DK2116244T3/da active
- 2004-05-13 BR BRPI0410273-8A patent/BRPI0410273A/pt not_active IP Right Cessation
- 2004-05-13 GE GEAP20049114A patent/GEP20084569B/en unknown
- 2004-05-13 SG SG200708456-9A patent/SG153667A1/en unknown
- 2004-05-13 MX MXPA05012272A patent/MXPA05012272A/es active IP Right Grant
- 2004-05-13 ES ES04785539T patent/ES2328148T3/es not_active Expired - Lifetime
- 2004-05-13 SI SI200431221T patent/SI1624871T1/sl unknown
- 2004-05-13 SI SI200431951T patent/SI2116244T1/sl unknown
- 2004-05-13 DK DK04785539T patent/DK1624871T3/da active
- 2004-05-13 GE GEAP200410277A patent/GEP20105025B/en unknown
- 2004-05-13 EA EA200702674A patent/EA011895B1/ru not_active IP Right Cessation
- 2004-05-13 ES ES09163448T patent/ES2392743T3/es not_active Expired - Lifetime
- 2004-05-13 CN CN2008101690579A patent/CN101559227B/zh not_active Expired - Fee Related
- 2004-05-13 AU AU2004240597A patent/AU2004240597B2/en not_active Ceased
- 2004-05-14 PA PA20048603201A patent/PA8603201A1/es unknown
- 2004-05-14 CL CL200401056A patent/CL2004001056A1/es unknown
- 2004-05-14 HN HN2004000171A patent/HN2004000171A/es unknown
- 2004-05-14 TW TW093113730A patent/TWI334354B/zh not_active IP Right Cessation
- 2004-05-14 TW TW096125297A patent/TWI341199B/zh not_active IP Right Cessation
- 2004-05-14 DO DO2004000907A patent/DOP2004000907A/es unknown
-
2005
- 2005-10-13 IS IS8071A patent/IS2708B/is unknown
- 2005-10-13 ZA ZA200508288A patent/ZA200508288B/xx unknown
- 2005-10-19 CR CR8047A patent/CR8047A/es unknown
- 2005-11-09 MA MA28589A patent/MA27835A1/fr unknown
- 2005-11-10 CO CO05114676A patent/CO5630034A2/es active IP Right Grant
- 2005-11-11 EC EC2005006156A patent/ECSP056156A/es unknown
- 2005-11-14 TN TNP2005000290A patent/TNSN05290A1/en unknown
- 2005-11-14 IL IL171962A patent/IL171962A/en not_active IP Right Cessation
- 2005-12-14 NO NO20055957A patent/NO20055957L/no not_active Application Discontinuation
-
2006
- 2006-12-11 HK HK06113584.9A patent/HK1092722A1/xx not_active IP Right Cessation
-
2008
- 2008-03-11 CR CR9808A patent/CR9808A/es not_active Application Discontinuation
-
2009
- 2009-05-21 US US12/470,049 patent/US20090233977A1/en not_active Abandoned
- 2009-07-31 HR HR20090424T patent/HRP20090424T1/xx unknown
- 2009-10-13 CY CY20091101051T patent/CY1109476T1/el unknown
- 2009-11-30 US US12/627,787 patent/US20100076002A1/en not_active Abandoned
- 2009-12-02 JP JP2009274146A patent/JP2010077151A/ja active Pending
-
2011
- 2011-01-24 US US13/012,696 patent/US20110118292A1/en not_active Abandoned
- 2011-03-07 AU AU2011200986A patent/AU2011200986B2/en not_active Ceased
-
2012
- 2012-10-11 HR HRP20120818TT patent/HRP20120818T1/hr unknown
- 2012-11-05 CY CY20121101050T patent/CY1113342T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
CO5600999A2 (es) | Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra | |
TW200716644A (en) | Aspartyl protease inhibitors | |
EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
LU93078I2 (fr) | Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib | |
CO5680428A2 (es) | Antagonistas del receptor de trombina | |
AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
TW200716567A (en) | Aspartyl protease inhibitors | |
SG162790A1 (en) | Aspartyl protease inhibitors | |
DE602005019316D1 (en) | Aromatische etherderivate als thrombin-hemmer | |
AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
ATE455103T1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
AR050160A1 (es) | Inhibisores heterociclicos de aspartil proteasa | |
DE602005016297D1 (de) | Antithrombotische diamide | |
BRPI0509074A (pt) | composições farmacêuticas compreendendo agonistas do receptor da tiróide | |
TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
WO2006002099A3 (en) | Factor xa inhibitors | |
ATE273305T1 (de) | Thrombin-inhibitoren | |
DE60130771D1 (de) | Substituierte heterocyclische amide | |
SE0400284D0 (sv) | Novel compounds | |
AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |